Switch to:

# Denali Therapeutics Revenue per Share

: \$1.43 (TTM As of Jun. 2019)
View and export this data going back to 2017. Start your Free Trial

Denali Therapeutics's revenue per share for the three months ended in Jun. 2019 was \$0.04. Denali Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Jun. 2019 was \$1.43.

During the past 12 months, the average Revenue Per Share Growth Rate of Denali Therapeutics was 5632.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

## Denali Therapeutics Revenue per Share Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

 Denali Therapeutics Annual Data Dec15 Dec16 Dec17 Dec18 Revenue per Share 0.00 0.00 0.00 1.39

 Denali Therapeutics Quarterly Data Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Revenue per Share 0.02 0.01 1.33 0.04 0.04

## Denali Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Denali Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2018 is calculated as

 Revenue Per Share (A: Dec. 2018 ) = Revenue (A: Dec. 2018 ) / Shares Outstanding (Diluted Average) (A: Dec. 2018 ) = 129.16 / 92.622 = 1.39

Denali Therapeutics's Revenue Per Share for the quarter that ended in Jun. 2019 is calculated as

 Revenue Per Share (Q: {Q1}) = Revenue (Q: Jun. 2019 ) / Shares Outstanding (Diluted Average) (Q: Jun. 2019 ) = 4.197 / 95.495 = 0.04

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2019 was 0.013 (Sep. 2018 ) + 1.332 (Dec. 2018 ) + 0.044 (Mar. 2019 ) + 0.044 (Jun. 2019 ) = \$1.43

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Denali Therapeutics  (NAS:DNLI) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.